[go: up one dir, main page]

MX391810B - Nuevo uso medico del compuesto iii. - Google Patents

Nuevo uso medico del compuesto iii.

Info

Publication number
MX391810B
MX391810B MX2019010003A MX2019010003A MX391810B MX 391810 B MX391810 B MX 391810B MX 2019010003 A MX2019010003 A MX 2019010003A MX 2019010003 A MX2019010003 A MX 2019010003A MX 391810 B MX391810 B MX 391810B
Authority
MX
Mexico
Prior art keywords
compound iii
medical use
new medical
diseases
polymorphs
Prior art date
Application number
MX2019010003A
Other languages
English (en)
Other versions
MX2019010003A (es
Inventor
Bodo Betzemeier
Daniel Jens Marckart
Holger Rosenbrock
Manabu Nakatani
Masanori Ito
Masashi Adachi
Michael Steven Sand
Riccardo Giovannini
Takayuki Kamata
Tobias Brodmann
Ulrike Werthmann
Yohei Kawabata
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019010003A publication Critical patent/MX2019010003A/es
Publication of MX391810B publication Critical patent/MX391810B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al Compuesto III para uso en el tratamiento de enfermedades en el espectro de la esquizofrenia y otros trastornos psicóticos, primeros episodios de estas enfermedades como el primer episodio psicótico (FEP), recaídas en estas enfermedades, y reducción de recaídas en pacientes con esquizofrenia (REX), a polimorfos del Compuesto III, y composiciones farmacéuticas que comprenden el Compuesto III y/o sus polimorfos.
MX2019010003A 2017-02-23 2018-02-21 Nuevo uso medico del compuesto iii. MX391810B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762462621P 2017-02-23 2017-02-23
US201762526393P 2017-06-29 2017-06-29
PCT/EP2018/054221 WO2018153887A1 (en) 2017-02-23 2018-02-21 New medical use of compound iii

Publications (2)

Publication Number Publication Date
MX2019010003A MX2019010003A (es) 2019-12-16
MX391810B true MX391810B (es) 2025-03-21

Family

ID=61569222

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010003A MX391810B (es) 2017-02-23 2018-02-21 Nuevo uso medico del compuesto iii.

Country Status (12)

Country Link
US (2) US10919898B2 (es)
EP (1) EP3585392A1 (es)
JP (1) JP7053645B2 (es)
KR (1) KR102643197B1 (es)
CN (1) CN110325193B (es)
AU (1) AU2018225373C1 (es)
CA (1) CA3051976A1 (es)
CL (1) CL2019002315A1 (es)
MX (1) MX391810B (es)
NZ (1) NZ755349A (es)
PH (1) PH12019501926A1 (es)
WO (1) WO2018153887A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008183929A (ja) * 2007-01-26 2008-08-14 Toshiba Corp Ｖｏｒモニタ受信装置及びｖｏｒモニタ受信方法
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2414363B1 (en) * 2009-03-31 2014-01-08 Boehringer Ingelheim International GmbH 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
PE20130602A1 (es) * 2010-08-12 2013-05-25 Boehringer Ingelheim Int Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
AU2013277294C1 (en) * 2012-06-18 2018-02-08 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
WO2017019723A1 (en) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Aza-cyanoquinolinone pde9 inhibitors
WO2017019724A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone pde9 inhibitors

Also Published As

Publication number Publication date
CN110325193A (zh) 2019-10-11
NZ755349A (en) 2025-03-28
WO2018153887A1 (en) 2018-08-30
AU2018225373A1 (en) 2019-08-01
AU2018225373B2 (en) 2022-02-03
US20180237445A1 (en) 2018-08-23
JP7053645B2 (ja) 2022-04-12
JP2020508320A (ja) 2020-03-19
KR20190120298A (ko) 2019-10-23
AU2018225373C1 (en) 2022-05-12
CN110325193B (zh) 2023-05-05
PH12019501926A1 (en) 2020-07-06
MX2019010003A (es) 2019-12-16
KR102643197B1 (ko) 2024-03-06
US20210130362A1 (en) 2021-05-06
CL2019002315A1 (es) 2019-12-27
US10919898B2 (en) 2021-02-16
CA3051976A1 (en) 2018-08-30
EP3585392A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
GEP20217316B (en) Aromatic sulfonamide derivatives
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CL2016002382A1 (es) Derivados de quinoxalina útiles como moduladores de fgfr quinasa
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2023002507A (es) Inhibidores de cd73.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
GEP20227443B (en) Magl inhibitors
BR112018005114A2 (pt) um novo polipeptídeo de endolisina
MX2017007637A (es) Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen.
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
EA201491505A1 (ru) Соединения для лечения спинальной мышечной атрофии
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
ZA202204941B (en) Cd73 inhibitors
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX392353B (es) Procedimientos para preparar compuestos de tipo oxatiazina
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
CL2011000165A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX387726B (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.